The AI-based Progression and Medication Response Prediction (AI-PMP) study is currently in preparation. After CHU de Toulouse submitted the study protocol in April 2025, the study has received ethics approval in France.

The protocol has also been submitted in Germany (Technical University of Dresden), and submission in Spain (Foundation for Initiatives in Neuroscience) is expected soon.

The AI-PMP study is a multi-centre, proof-of-concept study. It aims to:

• Validate AI models that predict Parkinson’s disease (PD) progression and medication response

• Provide preliminary evidence of clinical utility

• Evaluate the usability of the mAI-Care and mAI-Insights apps by people with PD and healthcare professionals.

The PD progression model uses a mix of clinical, genetic, and digital health data collected during daily life to help predict how the disease will develop. The AI-PMP study will help confirm how useful these AI models are in real clinical settings.

🔗 Read more about AI-PROGNOSIS clinical studies: https://www.ai-prognosis.eu/clinical-studies